Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday . The stock traded as high as $24.32 and last traded at $24.19, with a volume of 1046492 shares trading hands. The stock had previously closed at $23.00.
Wall Street Analyst Weigh In
Several equities analysts recently commented on CLBT shares. Craig Hallum increased their price objective on shares of Cellebrite DI from $23.00 to $24.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. increased their price objective on shares of Cellebrite DI from $22.00 to $24.00 and gave the company an "overweight" rating in a research note on Monday, December 16th. Finally, Needham & Company LLC increased their price objective on shares of Cellebrite DI from $21.00 to $28.00 and gave the company a "buy" rating in a research note on Wednesday, January 22nd. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Cellebrite DI currently has a consensus rating of "Buy" and an average target price of $21.57.
Check Out Our Latest Stock Analysis on CLBT
Cellebrite DI Price Performance
The company has a market cap of $4.95 billion, a price-to-earnings ratio of -15.51, a price-to-earnings-growth ratio of 3.54 and a beta of 1.46. The business's fifty day moving average price is $21.77 and its 200 day moving average price is $18.42.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.05. The business had revenue of $106.90 million for the quarter, compared to analyst estimates of $102.06 million. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. Cellebrite DI's revenue for the quarter was up 27.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.09 earnings per share. As a group, equities research analysts anticipate that Cellebrite DI Ltd. will post 0.32 EPS for the current year.
Hedge Funds Weigh In On Cellebrite DI
Several hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC increased its stake in Cellebrite DI by 136.3% in the third quarter. FMR LLC now owns 5,616,757 shares of the company's stock valued at $94,586,000 after purchasing an additional 3,239,307 shares in the last quarter. Meitav Investment House Ltd. increased its stake in Cellebrite DI by 29.7% in the third quarter. Meitav Investment House Ltd. now owns 2,066,322 shares of the company's stock valued at $34,797,000 after purchasing an additional 473,293 shares in the last quarter. Pembroke Management LTD increased its stake in Cellebrite DI by 4.4% in the fourth quarter. Pembroke Management LTD now owns 1,992,432 shares of the company's stock valued at $43,893,000 after purchasing an additional 84,087 shares in the last quarter. Principal Financial Group Inc. bought a new stake in shares of Cellebrite DI during the third quarter worth about $23,402,000. Finally, Two Sigma Advisers LP increased its position in shares of Cellebrite DI by 9.8% during the third quarter. Two Sigma Advisers LP now owns 1,341,100 shares of the company's stock worth $22,584,000 after acquiring an additional 120,000 shares in the last quarter. Institutional investors and hedge funds own 45.88% of the company's stock.
About Cellebrite DI
(
Get Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Articles
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
